Shots:

• The NMPA has granted approval to golidocitinib (JAK1 selective inhibitor) for treating r/r peripheral T-cell lymphoma (PTCL) adults whose disease progressed after at least 1 previous systemic therapy
• The approval was supported by a JACKPOT8 Part B (JACKPOT8B) trial assessing the safety & efficacy of golidocitinib monotx. to treat r/r PTCL
• The study, as of Aug 2023, depicted an ORR of 44.3% with CRR of 23.9% and mDoR of 20.7mos. with 53.8% of them still responding. Full data was highlighted at ASH 2023 & published in The Lancet Oncology

Ref: Dizal | Image: Dizal

Related News:- Dizal's Sunvozertinib Receives the NMPA’s Approval for Non-Small Cell Lung Cancer with EGFR Exon20ins Mutations

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com